Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $245
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsReiterationPrice Target
Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $225 to $245.
Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $225 to $245.